Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression
Semaglutide for weight management is approved for adults with a BMI of 30 or greater (obesity), or 27 or greater (overweight) with at least one weight-related comorbidity
Ozempic is administered as a once-weekly subcutaneous injection and is typically prescribed alongside diet and exercise modifications to improve glycaemic control
Tirzepatide, sold as Zepbound for weight management, activates GLP-1 receptors along with receptors for glucose-dependent insulinotropic polypeptide, or GIP, another hormone involved in appetite and blood-sugar regulation
This article explores one piece of that system
Some patients prescribed GLP-1 as part of a supervised program have reported: Semaglutide and Tirzepatide injections are self-administered at home following your providers instructions
